• Product Name — RARE CANNABINOID - THCV EDIBLE - HEAT RELIEF CBD ROLL-ON - LEMON - 25MG
    Where to Buy - Click Here to Rush Your Order from the Official Website
    Availability online Product link- https://clicks.trackcb.com/SH1w1
    ORDER NOW Satisfaction guaranteed or your money back
    Main Benefits — weight loss
    Extra Strength THCV Gummies
    25mg THCV per Gummy | Zero THC* | 15 Gummies per Bottle
    Our lemon-flavored THCV gummies contain a very high level of tetrahydrocannabivarin (THCV). THCV acts as a stimulant, increasing energy and suppressing appetite, which may aid weight loss. THCV is also being studied in relation to nicotine addiction and for potential benefits to mental and physical health. Click on the “Scientific Studies” tab for links to pre-clinical and clinical research. To experience our apothecary concept and enhance the effectiveness of our gummies, we recommend combining them with our CBD gummies.
    RELATED TAGS:-
    #HEAT RELIEF CBD ROLL-ON
    #HEAT RELIEF CBD ROLL-ON Price
    #HEAT RELIEF CBD ROLL-ON Buy
    #HEAT RELIEF CBD ROLL-ON Scam
    #HEAT RELIEF CBD ROLL-ON Offer
    #HEAT RELIEF CBD ROLL-ON Order
    #HEAT RELIEF CBD ROLL-ON result
    #HEAT RELIEF CBD ROLL-ON Benefits
    #HEAT RELIEF CBD ROLL-ON Reviews
    #HEAT RELIEF CBD ROLL-ON Ingredients
    #Wheretoget HEAT RELIEF CBD ROLL-ON Strength
    #HEAT RELIEF CBD ROLL-ON Sideeffects
    #HEATRELIEF CBD ROLL-ON SharkTankse
    Product Name — RARE CANNABINOID - THCV EDIBLE - HEAT RELIEF CBD ROLL-ON - LEMON - 25MG Where to Buy - Click Here to Rush Your Order from the Official Website Availability online Product link- https://clicks.trackcb.com/SH1w1 ORDER NOW Satisfaction guaranteed or your money back Main Benefits — weight loss Extra Strength THCV Gummies 25mg THCV per Gummy | Zero THC* | 15 Gummies per Bottle Our lemon-flavored THCV gummies contain a very high level of tetrahydrocannabivarin (THCV). THCV acts as a stimulant, increasing energy and suppressing appetite, which may aid weight loss. THCV is also being studied in relation to nicotine addiction and for potential benefits to mental and physical health. Click on the “Scientific Studies” tab for links to pre-clinical and clinical research. To experience our apothecary concept and enhance the effectiveness of our gummies, we recommend combining them with our CBD gummies. RELATED TAGS:- #HEAT RELIEF CBD ROLL-ON #HEAT RELIEF CBD ROLL-ON Price #HEAT RELIEF CBD ROLL-ON Buy #HEAT RELIEF CBD ROLL-ON Scam #HEAT RELIEF CBD ROLL-ON Offer #HEAT RELIEF CBD ROLL-ON Order #HEAT RELIEF CBD ROLL-ON result #HEAT RELIEF CBD ROLL-ON Benefits #HEAT RELIEF CBD ROLL-ON Reviews #HEAT RELIEF CBD ROLL-ON Ingredients #Wheretoget HEAT RELIEF CBD ROLL-ON Strength #HEAT RELIEF CBD ROLL-ON Sideeffects #HEATRELIEF CBD ROLL-ON SharkTankse
    0 Comments 0 Shares
  • Kaiser Permanente Login | Kaiser Permanente Login Member

    Kaiser Permanente is the country’s most extensive not-for-profit health plan that provides health education, care innovations, and clinical research that supports the world.
    #KaiserPermanenteLogin
    Visit here;- https://kaisorpermanante-logi.com/
    Kaiser Permanente Login | Kaiser Permanente Login Member Kaiser Permanente is the country’s most extensive not-for-profit health plan that provides health education, care innovations, and clinical research that supports the world. #KaiserPermanenteLogin Visit here;- https://kaisorpermanante-logi.com/
    0 Comments 0 Shares
  • are really rare. These capsules are a successful weight-loss aid since this is thought to be the result of extensive clinical research that includes a lot of ketones. It only uses natural ingredients and processes. https://wyattconn.blog-a-story.com/20272711/glucofort-is-a-famous-blood-sugar-stabilizer
    https://haileyadams.widblog.com/69284178/that-regulates-insulin-hormone-production
    https://maudhoppe.getblogs.net/45785796/you-may-devour-the-encouraged-dosage
    https://flaviowalsh.fireblogz.com/45638122/glucofort-and-stay-wholesomehttps://www.exposedmagazine.co.uk/features/figur-slimming-tablets-dragons-den-uk-latest-reviews-2022/
    are really rare. These capsules are a successful weight-loss aid since this is thought to be the result of extensive clinical research that includes a lot of ketones. It only uses natural ingredients and processes. https://wyattconn.blog-a-story.com/20272711/glucofort-is-a-famous-blood-sugar-stabilizer https://haileyadams.widblog.com/69284178/that-regulates-insulin-hormone-production https://maudhoppe.getblogs.net/45785796/you-may-devour-the-encouraged-dosage https://flaviowalsh.fireblogz.com/45638122/glucofort-and-stay-wholesomehttps://www.exposedmagazine.co.uk/features/figur-slimming-tablets-dragons-den-uk-latest-reviews-2022/
    Glucofort is a famous blood sugar stabilizer
    Glucofort is a famous blood sugar stabilizer
    WYATTCONN.BLOG-A-STORY.COM
    0 Comments 0 Shares
  • are really rare. These capsules are a successful weight-loss aid since this is thought to be the result of extensive clinical research that includes a lot of ketones. It only uses natural ingredients and processes. It is said that getting to the top rank is simpler than staying there. This method is https://kaelalang.blog-eye.com/15964742/lets-keto-apple-gummies
    https://ottisauer.bcbloggers.com/17632055/lets-keto-apple-gummies
    https://evaharvey.activablog.com/17284837/lets-keto-apple-gummies
    https://hildaveum.ageeksblog.com/17324332/lets-keto-apple-gummies https://catherinehardwicke.com/bleame-hair-eraser-reviews/
    https://www.exposedmagazine.co.uk/features/figur-slimming-tablets-dragons-den-uk-latest-reviews-2022/
    are really rare. These capsules are a successful weight-loss aid since this is thought to be the result of extensive clinical research that includes a lot of ketones. It only uses natural ingredients and processes. It is said that getting to the top rank is simpler than staying there. This method is https://kaelalang.blog-eye.com/15964742/lets-keto-apple-gummies https://ottisauer.bcbloggers.com/17632055/lets-keto-apple-gummies https://evaharvey.activablog.com/17284837/lets-keto-apple-gummies https://hildaveum.ageeksblog.com/17324332/lets-keto-apple-gummies https://catherinehardwicke.com/bleame-hair-eraser-reviews/ https://www.exposedmagazine.co.uk/features/figur-slimming-tablets-dragons-den-uk-latest-reviews-2022/
    Lets Keto Apple Gummies
    Lets Keto Apple Gummies
    KAELALANG.BLOG-EYE.COM
    0 Comments 0 Shares
  • Why is Project Management Essential in Clinical Research?

    Clinical research and project management have a similar structure that is kept in mind while drafting the concerned systematic plans. Under the umbrella of clinical research come clinical trials, which have a complex web of systematic projects. Project management methods require constant planning under the supervision of an executive who has knowledge of project management methods.
    A project management approach to clinical research
    Expert or not, every involved clinical research entity needs to know these basic project management skills for effective employment of resources to their potential.
    Hire a supervisor for project management.
    A better option would be a project manager who keeps tabs on multiple projects simultaneously. He is the go-to person in the event of not having access to any task-related information. Stakeholders require every insightful update of the planned process to make any adjustments if required. As a result, make certain that you hire the best personnel who will prove to be a valuable asset.
    Open the doors of communication with the crew.
    Every project is based on getting a clear and bigger picture of the task at hand. A project manager gets every involved individual on the same page by organizing meetings for follow-up purposes while keeping everything in check.
    Go through the process and plot the relevant approach.
    The effectiveness of any plan would be evaluated when every step of the process is evaluated within the defined period of time. Thus, the project management team is required to adopt any required modifications using performance-based indicators. Keep the stakeholders and team members in the loop while implementing any modifications in the process by conveying key findings from your task.
    Making data accessible by saving information at a secure location
    Extraction of required information could be a task when working on multiple projects at the same time. Therefore, save all the useful data in one place for easy tracking.
    Endnote
    Applying project management principles in the clinical research industry helps in shaping the structure of managerial tasks. Having a professional project manager oversee every trial-related task increases the overall efficiency. As the clinical trial requires the project manager to maintain equilibrium of every task, a project manager can provide their proficiency gained through experience in handling responsible tasks. Adopt the project management approach while handling critical clinical research tasks. This would accelerate the pace of clinical research due to well-organized clinical trial-project performance.
    https://www.technobridge.in/regulatory-affairs-courses.php
    https://www.technobridge.in/pharmacovigilance-courses.php

    Why is Project Management Essential in Clinical Research? Clinical research and project management have a similar structure that is kept in mind while drafting the concerned systematic plans. Under the umbrella of clinical research come clinical trials, which have a complex web of systematic projects. Project management methods require constant planning under the supervision of an executive who has knowledge of project management methods. A project management approach to clinical research Expert or not, every involved clinical research entity needs to know these basic project management skills for effective employment of resources to their potential. Hire a supervisor for project management. A better option would be a project manager who keeps tabs on multiple projects simultaneously. He is the go-to person in the event of not having access to any task-related information. Stakeholders require every insightful update of the planned process to make any adjustments if required. As a result, make certain that you hire the best personnel who will prove to be a valuable asset. Open the doors of communication with the crew. Every project is based on getting a clear and bigger picture of the task at hand. A project manager gets every involved individual on the same page by organizing meetings for follow-up purposes while keeping everything in check. Go through the process and plot the relevant approach. The effectiveness of any plan would be evaluated when every step of the process is evaluated within the defined period of time. Thus, the project management team is required to adopt any required modifications using performance-based indicators. Keep the stakeholders and team members in the loop while implementing any modifications in the process by conveying key findings from your task. Making data accessible by saving information at a secure location Extraction of required information could be a task when working on multiple projects at the same time. Therefore, save all the useful data in one place for easy tracking. Endnote Applying project management principles in the clinical research industry helps in shaping the structure of managerial tasks. Having a professional project manager oversee every trial-related task increases the overall efficiency. As the clinical trial requires the project manager to maintain equilibrium of every task, a project manager can provide their proficiency gained through experience in handling responsible tasks. Adopt the project management approach while handling critical clinical research tasks. This would accelerate the pace of clinical research due to well-organized clinical trial-project performance. https://www.technobridge.in/regulatory-affairs-courses.php https://www.technobridge.in/pharmacovigilance-courses.php
    Best Regulatory Affairs Courses in India with 100% Placement
    TechnoBridge Offers Regulatory Affairs Courses with 100% placement in India. Get best career, scope, salary, fees, Eligibility in Regulatory Affairs courses.
    WWW.TECHNOBRIDGE.IN
    0 Comments 0 Shares
  • Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million in 2030

    Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
    Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million in 2030 Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
    Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing | Industry Analysis | Market Size | 2030
    The Novel Immuno-Oncology / Cancer Biomarker Testing market is anticipated to grow at an annualized rate of ~18% over the next decade
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million

    Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
    Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
    Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing | Industry Analysis | Market Size | 2030
    The Novel Immuno-Oncology / Cancer Biomarker Testing market is anticipated to grow at an annualized rate of ~18% over the next decade
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030

    Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance

    Roots Analysis has announced the addition of “Soft Tissue Sarcoma: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings.

    Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified. However, since these tumors possess a large set of entities, their diagnosis is often difficult. At present, there is a growing need for effective and targeted treatment options.

    To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html.

    Key Market Insights

    70+ therapeutics have been / are being developed for the treatment of angiosarcoma, chondrosarcoma and liposarcoma
    Nearly 95% of the aforementioned therapeutic candidates are under clinical evaluation. Further, two therapies, namely YONDELIS® and HALAVEN®, have been approved for the treatment of liposarcoma.

    Around 65% of the therapeutics are being developed as small molecules
    Majority (over 65%) of the abovementioned drugs have been / are being developed for administration via the oral route. Notably, about 60% of the soft tissue sarcoma targeting therapeutics have been / are being developed for use as the 1st line of treatment.

    More than 50 industry and non-industry players are engaged in the soft tissue sarcoma market
    North America has emerged as a key hub, featuring the presence of close to 60% developers. The developer landscape is further dominated by players that have been established after 1990, representing around 45% of the total number of stakeholders.

    Around 190 trials, evaluating therapies for soft tissue sarcoma, have been registered
    More than 22,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy and safety of soft tissue sarcoma targeting therapeutics. Interestingly, 60% of the overall trials are phase II studies; of these, 50% are currently active.

    Partnership activity in this field has increased at a CAGR of 70%, between 2018 and 2020
    About 80% of the reported deals were established in the last three years, with the maximum activity being reported in 2020. Majority of the instances captured in the report were licensing agreements (45%). Further, more than 50% of the agreements were observed to be signed for therapeutics targeting liposarcoma.

    More than 260 articles have been published related to soft tissue sarcoma, since January 2021
    Around 40% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of angiosarcoma. Example of prominent journals include (in decreasing order of number of publications) BMJ Case Rep, Skeletal Radiol, Ann Surg Oncol and Cureus.

    Around 75 eminent scientists were identified as key opinion leaders (KOLs)
    65% of these KOLs were observed to be associated with organizations based in North America, followed by those affiliated to institutes in Europe (30%) and Asia-Pacific (5%). Further, majority (50%) of the KOLs are currently affiliated to academic institutes, such as schools and universities.

    North America is anticipated to capture over 70% of the global market share in 2030
    In 2030, nearly 80% of the market revenues are expected to be generated from sales of therapeutics that intended for the treatment of liposarcoma. Further, therapies designed for intravenous administration are expected to occupy a larger share (60%) of the overall market in 2030.

    To request a sample copy / brochure of this report, please visit this
    https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market/request-sample.html

    Key Questions Answered
     Who are the leading players engaged in the development of soft tissue sarcoma targeting therapeutics?
     Which is the most popular type of soft tissue sarcoma, based on the ongoing activity in the market?
     Which are the most common routes of administration for soft tissue sarcoma targeting therapeutics?
     Which companies are actively involved in conducting clinical trials for their therapeutic candidates?
     Which partnership models are most commonly adopted by stakeholders in this industry?
     What is the evolving trend related to the focus of publications related to soft tissue sarcoma targeting therapeutics?
     Who are the prominent KOLs evaluating therapies within this industry?
     What opportunities are available for soft tissue sarcoma targeting therapeutics in emerging markets?
     How is the current and future opportunity likely to be distributed across key market segments?


    The USD 421 million (by 2030) financial opportunity within the soft tissue sarcoma targeting therapeutics market has been analyzed across the following segments:

     Drug Class
     Biologics
     Small Molecules

     Route of Administration
     Intravenous Drugs
     Oral Drugs

     Type of Soft Tissue Sarcoma
     Angiosarcoma
     Chondrosarcoma
     Liposarcoma

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific
     Rest of the World

    The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.

     Adaptimmune
     Agios Pharmaceuticals
     Agenus
     Athenex
     Eisai
     Eli Lilly
     GlaxoSmithKline
     Karyopharm Therapeutics
     Mirati Therapeutics
     PharmaMar

    For additional details, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030 Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance Roots Analysis has announced the addition of “Soft Tissue Sarcoma: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings. Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified. However, since these tumors possess a large set of entities, their diagnosis is often difficult. At present, there is a growing need for effective and targeted treatment options. To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html. Key Market Insights 70+ therapeutics have been / are being developed for the treatment of angiosarcoma, chondrosarcoma and liposarcoma Nearly 95% of the aforementioned therapeutic candidates are under clinical evaluation. Further, two therapies, namely YONDELIS® and HALAVEN®, have been approved for the treatment of liposarcoma. Around 65% of the therapeutics are being developed as small molecules Majority (over 65%) of the abovementioned drugs have been / are being developed for administration via the oral route. Notably, about 60% of the soft tissue sarcoma targeting therapeutics have been / are being developed for use as the 1st line of treatment. More than 50 industry and non-industry players are engaged in the soft tissue sarcoma market North America has emerged as a key hub, featuring the presence of close to 60% developers. The developer landscape is further dominated by players that have been established after 1990, representing around 45% of the total number of stakeholders. Around 190 trials, evaluating therapies for soft tissue sarcoma, have been registered More than 22,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy and safety of soft tissue sarcoma targeting therapeutics. Interestingly, 60% of the overall trials are phase II studies; of these, 50% are currently active. Partnership activity in this field has increased at a CAGR of 70%, between 2018 and 2020 About 80% of the reported deals were established in the last three years, with the maximum activity being reported in 2020. Majority of the instances captured in the report were licensing agreements (45%). Further, more than 50% of the agreements were observed to be signed for therapeutics targeting liposarcoma. More than 260 articles have been published related to soft tissue sarcoma, since January 2021 Around 40% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of angiosarcoma. Example of prominent journals include (in decreasing order of number of publications) BMJ Case Rep, Skeletal Radiol, Ann Surg Oncol and Cureus. Around 75 eminent scientists were identified as key opinion leaders (KOLs) 65% of these KOLs were observed to be associated with organizations based in North America, followed by those affiliated to institutes in Europe (30%) and Asia-Pacific (5%). Further, majority (50%) of the KOLs are currently affiliated to academic institutes, such as schools and universities. North America is anticipated to capture over 70% of the global market share in 2030 In 2030, nearly 80% of the market revenues are expected to be generated from sales of therapeutics that intended for the treatment of liposarcoma. Further, therapies designed for intravenous administration are expected to occupy a larger share (60%) of the overall market in 2030. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of soft tissue sarcoma targeting therapeutics?  Which is the most popular type of soft tissue sarcoma, based on the ongoing activity in the market?  Which are the most common routes of administration for soft tissue sarcoma targeting therapeutics?  Which companies are actively involved in conducting clinical trials for their therapeutic candidates?  Which partnership models are most commonly adopted by stakeholders in this industry?  What is the evolving trend related to the focus of publications related to soft tissue sarcoma targeting therapeutics?  Who are the prominent KOLs evaluating therapies within this industry?  What opportunities are available for soft tissue sarcoma targeting therapeutics in emerging markets?  How is the current and future opportunity likely to be distributed across key market segments? The USD 421 million (by 2030) financial opportunity within the soft tissue sarcoma targeting therapeutics market has been analyzed across the following segments:  Drug Class  Biologics  Small Molecules  Route of Administration  Intravenous Drugs  Oral Drugs  Type of Soft Tissue Sarcoma  Angiosarcoma  Chondrosarcoma  Liposarcoma  Key Geographical Regions  North America  Europe  Asia-Pacific  Rest of the World The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.  Adaptimmune  Agios Pharmaceuticals  Agenus  Athenex  Eisai  Eli Lilly  GlaxoSmithKline  Karyopharm Therapeutics  Mirati Therapeutics  PharmaMar For additional details, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • The CAR-T therapies market is characterized by a healthy pipeline of promising therapies

    Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market

    Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings.

    Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.

    To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

    Key Market Insights

    Over 755 CAR-T cell therapies are currently approved / under development
    Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528.

    Currently, the focus is on developing product candidates to treat various types of cancers
    Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications.

    Extensive efforts are underway to improve CAR constructs
    Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide.

    China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals
    In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field.

    Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020
    More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%).

    Over USD 13 billion has been invested by both private and public investors, across more than 205 instances
    It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%).

    The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030
    Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues.

    To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html

    Key Questions Answered
     Who are the leading industry and non-industry players in this market?
     What are the prevalent R&D trends in CAR-T cell therapies domain?
     What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?
     What are the challenges faced by stakeholders in this industry?
     Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?
     Who are the key investors in this domain?
     Who are the key opinion leaders / experts that can help in driving product development efforts in this field?
     What kind of partnership models are commonly adopted by industry stakeholders?
     What kind of contract manufacturing support is available for CAR-T cell therapies?
     What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?
     What are the factors that are likely to influence the evolution of this upcoming market?
     How is the current and future market opportunity likely to be distributed across key market segments?


    The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:

     Disease indication
     Non-Hodgkin lymphoma
     Multiple myeloma
     Chronic lymphocytic leukemia
     Acute lymphoblastic leukemia
     Follicular lymphoma
     Mantle cell lymphoma
     Hepatocellular carcinoma
     Colorectal cancer

     Target antigens
     CD19
     BCMA
     CD19, CD22
     GPC3
     EGFR

     Key Geographical Regions
     North America
     Europe
     Asia Pacific
     Latin America
     Middle East and North Africa
     Rest of the World

    The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:
     Tim Oldham (Chief Executive Officer, Cell Therapies)
     Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
     Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
     Miguel Forte (Chief Operating Officer, TxCell)
     Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
     Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
     Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
     Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
     Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
     Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

    The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.
     Autolus
     bluebird bio
     CARsgen Therapeutics
     Celgene (A Bristol Myers Squibb Company)
     Cellectis
     Cellular Biomedicine Group
     Innovative Cellular Therapeutics
     Iovance Biotherapeutics
     Kite Pharma (A Gilead Sciences Company)
     Kuur Therapeutics
     Noile-Immune Biotech
     Novartis
     Shanghai Genechem
     Sinobioway Cell Therapy
     Takara Bio
     Ziopharm Oncology

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030
    2. mRNA Therapeutics and Vaccines Market, 2020-2030
    3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
    4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The CAR-T therapies market is characterized by a healthy pipeline of promising therapies Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings. Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity. To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html Key Market Insights Over 755 CAR-T cell therapies are currently approved / under development Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528. Currently, the focus is on developing product candidates to treat various types of cancers Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications. Extensive efforts are underway to improve CAR constructs Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide. China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field. Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020 More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%). Over USD 13 billion has been invested by both private and public investors, across more than 205 instances It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%). The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030 Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html Key Questions Answered  Who are the leading industry and non-industry players in this market?  What are the prevalent R&D trends in CAR-T cell therapies domain?  What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?  What are the challenges faced by stakeholders in this industry?  Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?  Who are the key investors in this domain?  Who are the key opinion leaders / experts that can help in driving product development efforts in this field?  What kind of partnership models are commonly adopted by industry stakeholders?  What kind of contract manufacturing support is available for CAR-T cell therapies?  What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?  What are the factors that are likely to influence the evolution of this upcoming market?  How is the current and future market opportunity likely to be distributed across key market segments? The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:  Disease indication  Non-Hodgkin lymphoma  Multiple myeloma  Chronic lymphocytic leukemia  Acute lymphoblastic leukemia  Follicular lymphoma  Mantle cell lymphoma  Hepatocellular carcinoma  Colorectal cancer  Target antigens  CD19  BCMA  CD19, CD22  GPC3  EGFR  Key Geographical Regions  North America  Europe  Asia Pacific  Latin America  Middle East and North Africa  Rest of the World The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:  Tim Oldham (Chief Executive Officer, Cell Therapies)  Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)  Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)  Miguel Forte (Chief Operating Officer, TxCell)  Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)  Vincent Brichard (Vice President, Immuno-Oncology, Celyad)  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)  Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)  Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)  Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.  Autolus  bluebird bio  CARsgen Therapeutics  Celgene (A Bristol Myers Squibb Company)  Cellectis  Cellular Biomedicine Group  Innovative Cellular Therapeutics  Iovance Biotherapeutics  Kite Pharma (A Gilead Sciences Company)  Kuur Therapeutics  Noile-Immune Biotech  Novartis  Shanghai Genechem  Sinobioway Cell Therapy  Takara Bio  Ziopharm Oncology For additional details, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030 2. mRNA Therapeutics and Vaccines Market, 2020-2030 3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030 4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    CAR-T Therapies Market (3rd Edition) | Industry Analysis | Market Size | 2030
    CAR-T Therapies market report features an extensive study of the current market landscape and future potential of the industry players
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The CD-47 targeting therapeutics market is projected to grow at a CAGR of 42.9%, claims Roots Analysis

    Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes.

    Roots Analysis has announced the addition of “CD-47 Targeting Therapeutics Market, 2021-2035” report to its list of offerings.

    In recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. CD-47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker.

    To order this 190+ page report, which features 142+ figures, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html

    Key Market Insights

    Over 75 CD-47 drug candidates are under various phases of development
    52% of the pipeline candidates are currently in preclinical and discovery stages, while more than 48% therapies are being evaluated in clinical stages with most candidates being in early clinical stages (41.6%); 3.9% and 2.6% of clinical candidates being evaluated in phase II and phase III respectively.

    ~50 companies claim to be engaged in the development of CD-47 therapeutics, globally
    Since 2015, 13 companies have been established in this domain. Further, around 44% of the industry stakeholders are small companies. In addition, majority (47%) of the CD-47 therapeutics developers are based in North America, primarily in the US.

    Several clinical trials evaluating CD-47 targeting therapeutics have been registered worldwide
    Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 34.1%, during the period 2015-2020. Of the total, close to 13% of the studies have already been completed, followed by active trials that are actively recruiting patients (46.7%).

    Partnership activity within this domain has increased at a CAGR of 25.7%, between 2016 and 2020
    Clinical trial agreements emerged as the most popular type of partnership model adopted by industry stakeholders, followed by product development and commercialization agreements (25%), licensing agreements (25%), and services agreements (7.1%).

    USD 3.3+ billion has been invested by both private and public investors
    It is important to mention that, between 2016 and 2021, majority of the funding amount was raised through secondary offerings (46.5%), venture capital rounds (45%), IPO (15.6%) and debt financing (7.4%).

    North America is anticipated to capture over 85% of the market share, by 2035
    The market will be primarily driven by sales of CD-47 based therapeutics designed as biologics (over 60%), followed by those developed as small molecules (over 39%). Further, CD-47 based therapies targeting non-small cell lung cancer will capture the dominant share (23%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future.

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html

    Key Questions Answered

     Who are the leading players engaged in the development of CD47 targeting therapeutics?
     Which are the key drugs being developed across early and late stages of development?
     Which companies are actively involved in conducting clinical trials for their therapeutics?
     What is the evolving trend related to the focus of publications related to CD47 targeting therapeutics?
     What kind of partnership models are commonly adopted by industry stakeholders?
     Who are the key investors in this domain?
     Who are the key opinion leaders / experts in this field?
     What are the evolving social media trends related to CD47 targeting therapeutics?
     What are the different initiatives undertaken by big pharma players for the development of CD47 therapeutics in the recent past?
     How is the current and future opportunity likely to be distributed across key market segments?

    The financial opportunity within the CD-47 targeting therapeutics market has been analyzed across the following segments:
     Type of Molecule
     Biologics
     Small molecules

     Target Indications
     Acute Myeloid Leukemia
     Colorectal Neoplasms
     Diffuse-Large Cell Lymphoma
     Myelodysplastic Syndromes
     Non-Hodgkin Lymphoma
     Non-Small Cell Lung Cancer
     Oral Muscositis
     Ovarian Epithelial Cancer
     Small Cell Lung Cancer

     Key Players

     Key Geographical Regions
     US
     France
     Germany
     Italy
     Spain
     UK
     Australia
     China
     India
     Israel

    The research includes detailed profiles of 10+ developers by (listed below); the profiles also feature an overview of the developer, its financial information (if available), recent developments and an informed future outlook.

     Abpro
     ALX Oncology
     Apmonia Therapeutics
     Arch Oncology
     Aurigene
     Bristol Myers Squibb
     EpicentRx
     Forty Seven
     ImmuneOncia Therapeutics
     ImmuneOnco Biopharmaceuticals
     Innovent Biologics
     KAHR Medical
     Light Chain Bioscience
     Morphiex
     Trillium Therapeutics

    For additional details, please visit
    https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. RAS Targeting Therapies Market, 2021-2031
    2. Squamous NSCLC Market, 2021-2031
    3. Peptide Therapeutics Market, 2021-2031

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The CD-47 targeting therapeutics market is projected to grow at a CAGR of 42.9%, claims Roots Analysis Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes. Roots Analysis has announced the addition of “CD-47 Targeting Therapeutics Market, 2021-2035” report to its list of offerings. In recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. CD-47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker. To order this 190+ page report, which features 142+ figures, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html Key Market Insights Over 75 CD-47 drug candidates are under various phases of development 52% of the pipeline candidates are currently in preclinical and discovery stages, while more than 48% therapies are being evaluated in clinical stages with most candidates being in early clinical stages (41.6%); 3.9% and 2.6% of clinical candidates being evaluated in phase II and phase III respectively. ~50 companies claim to be engaged in the development of CD-47 therapeutics, globally Since 2015, 13 companies have been established in this domain. Further, around 44% of the industry stakeholders are small companies. In addition, majority (47%) of the CD-47 therapeutics developers are based in North America, primarily in the US. Several clinical trials evaluating CD-47 targeting therapeutics have been registered worldwide Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 34.1%, during the period 2015-2020. Of the total, close to 13% of the studies have already been completed, followed by active trials that are actively recruiting patients (46.7%). Partnership activity within this domain has increased at a CAGR of 25.7%, between 2016 and 2020 Clinical trial agreements emerged as the most popular type of partnership model adopted by industry stakeholders, followed by product development and commercialization agreements (25%), licensing agreements (25%), and services agreements (7.1%). USD 3.3+ billion has been invested by both private and public investors It is important to mention that, between 2016 and 2021, majority of the funding amount was raised through secondary offerings (46.5%), venture capital rounds (45%), IPO (15.6%) and debt financing (7.4%). North America is anticipated to capture over 85% of the market share, by 2035 The market will be primarily driven by sales of CD-47 based therapeutics designed as biologics (over 60%), followed by those developed as small molecules (over 39%). Further, CD-47 based therapies targeting non-small cell lung cancer will capture the dominant share (23%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html Key Questions Answered  Who are the leading players engaged in the development of CD47 targeting therapeutics?  Which are the key drugs being developed across early and late stages of development?  Which companies are actively involved in conducting clinical trials for their therapeutics?  What is the evolving trend related to the focus of publications related to CD47 targeting therapeutics?  What kind of partnership models are commonly adopted by industry stakeholders?  Who are the key investors in this domain?  Who are the key opinion leaders / experts in this field?  What are the evolving social media trends related to CD47 targeting therapeutics?  What are the different initiatives undertaken by big pharma players for the development of CD47 therapeutics in the recent past?  How is the current and future opportunity likely to be distributed across key market segments? The financial opportunity within the CD-47 targeting therapeutics market has been analyzed across the following segments:  Type of Molecule  Biologics  Small molecules  Target Indications  Acute Myeloid Leukemia  Colorectal Neoplasms  Diffuse-Large Cell Lymphoma  Myelodysplastic Syndromes  Non-Hodgkin Lymphoma  Non-Small Cell Lung Cancer  Oral Muscositis  Ovarian Epithelial Cancer  Small Cell Lung Cancer  Key Players  Key Geographical Regions  US  France  Germany  Italy  Spain  UK  Australia  China  India  Israel The research includes detailed profiles of 10+ developers by (listed below); the profiles also feature an overview of the developer, its financial information (if available), recent developments and an informed future outlook.  Abpro  ALX Oncology  Apmonia Therapeutics  Arch Oncology  Aurigene  Bristol Myers Squibb  EpicentRx  Forty Seven  ImmuneOncia Therapeutics  ImmuneOnco Biopharmaceuticals  Innovent Biologics  KAHR Medical  Light Chain Bioscience  Morphiex  Trillium Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. RAS Targeting Therapies Market, 2021-2031 2. Squamous NSCLC Market, 2021-2031 3. Peptide Therapeutics Market, 2021-2031 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    CD-47 Targeting Therapeutics | Industry Analysis | Market Size | 2030
    CD-47 Targeting Therapeutics Market report features an extensive study of the current market...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

No results to show

Sponsored